Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,674 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05757973 | Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Dec 9, 2025 | clinicaltrials |
| NCT05164250 | Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) | approved for marketing | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Nov 10, 2025 |
| clinicaltrials |
| NCT05463939 | Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 15, 2025 | clinicaltrials |
| NCT01833039 | An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | approved for marketing | — | — | Janssen Biotech, Inc.INDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT05172700 | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | approved for marketing | — | — | Loxo Oncology, Inc.INDUSTRY | 0 | Dec 18, 2024 | clinicaltrials |
| NCT05733650 | Expanded Access Program for Epcoritamab | approved for marketing | — | — | GenmabINDUSTRY | 0 | May 25, 2023 | clinicaltrials |
| NCT04162756 | Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies(ZUMA-18) | approved for marketing | — | — | Kite, A Gilead CompanyINDUSTRY | 1 | Oct 14, 2021 | clinicaltrials |
| NCT04943952 | JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 0 | Aug 3, 2021 | clinicaltrials |
| NCT03070093 | Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | approved for marketing | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Apr 20, 2021 | clinicaltrials |
| NCT03723135 | Expanded Access for CC-486 | approved for marketing | — | — | CelgeneINDUSTRY | 1 | Sep 18, 2020 | clinicaltrials |
| NCT04300803 | Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL | approved for marketing | — | — | MorphoSys AGINDUSTRY | 0 | Aug 28, 2020 | clinicaltrials |
| NCT01632826 | Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma(PEXIUS) | approved for marketing | — | — | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT02477891 | Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 6 | Jan 15, 2019 | clinicaltrials |
| NCT03245424 | Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation | approved for marketing | — | — | Agios Pharmaceuticals, Inc.INDUSTRY | 0 | Jul 24, 2018 | clinicaltrials |
| NCT01869803 | Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | approved for marketing | — | — | Wake Forest University Health SciencesOTHER | 1 | Mar 2, 2018 | clinicaltrials |
| NCT01592136 | Expanded Access Program of Ponatinib | approved for marketing | — | — | Ariad PharmaceuticalsINDUSTRY | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01410500 | Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease | approved for marketing | — | — | AmgenINDUSTRY | 0 | May 2, 2017 | clinicaltrials |
| NCT02437019 | Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | approved for marketing | — | — | Janssen-Cilag Farmaceutica Ltda.INDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT02136511 | Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia | approved for marketing | — | — | Gilead SciencesINDUSTRY | 4 | Oct 28, 2014 | clinicaltrials |
| NCT00905593 | Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(ENACT) | approved for marketing | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 18, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Dec 9, 2025source: clinicaltrials